0001564590-21-003480.txt : 20210201 0001564590-21-003480.hdr.sgml : 20210201 20210201063021 ACCESSION NUMBER: 0001564590-21-003480 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210201 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210201 DATE AS OF CHANGE: 20210201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quotient Ltd CENTRAL INDEX KEY: 0001596946 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 264719797 STATE OF INCORPORATION: Y9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36415 FILM NUMBER: 21574238 BUSINESS ADDRESS: STREET 1: 28 ESPLANADE CITY: SAINT HELIER STATE: Y9 ZIP: JE2 3QA BUSINESS PHONE: 41274832286 MAIL ADDRESS: STREET 1: 28 ESPLANADE CITY: SAINT HELIER STATE: Y9 ZIP: JE2 3QA 8-K 1 qtnt-8k_20210201.htm 8-K qtnt-8k_20210201.htm
false Quotient Ltd 0001596946 00-0000000 0001596946 2021-02-01 2021-02-01

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

—————————

FORM 8-K

—————————

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1, 2021 (February 1, 2021)

—————————

QUOTIENT LIMITED
(Exact name of registrant as specified in its charter)

 

Jersey, Channel Islands

001-36415

Not Applicable

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

B1, Business Park Terre Bonne,
Route de Crassier 13,
1262 Eysins, Switzerland

Not Applicable

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: 011-41-22-716-9800

n/a
(Former name or former address, if changed since last report.)

—————————

Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)

 

☐

Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))

 

☐

Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

Name of exchange on which registered

Ordinary Shares, nil par value

 

QTNT

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On February 1, 2021, Quotient Limited issued an earnings release announcing its financial results for the quarter ended December 31, 2020.  A copy of the earnings release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

The information in this Current Report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.  The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, unless it is specifically incorporated by reference therein.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

NumberDescription

 

Exhibit 99.1Earnings Release, dated February 1, 2021

 

Exhibit 104The cover page for this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101)

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

QUOTIENT LIMITED

 

By:

 

/s/ Franz Walt

 

Name: Franz Walt

 

Title: Chief Executive Officer

Date: February 1, 2021

 

 

 

 EX-99.1 2 qtnt-ex991_25.htm EX-99.1 qtnt-ex991_25.htm

Exhibit 99.1

 

 

 

 

 

Quotient Limited Reports Third Quarter Fiscal 2021 Results
and Business Update

 

•

MosaiQ COVID-19 semi-quantitative antibody test CE marked

 

•

Expanded MosaiQ IH microarray EU launch planned for fourth quarter CY2021

 

•

Sales of Alba by Quotient reagents exceed guidance

 

•

Strong cash position in place to carry us into commercialization

 

JERSEY, Channel Islands, February 1, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2021 results and other notable developments.

Notable developments include the CE marking of the Company's MosaiQ semi-quantitative COVID-19 antibody test, which is an enhanced version of the Company's previously approved COVID antibody test. The enhanced test will allow users to determinate the relative concentration levels of antibodies present in a sample. The Company believes this functionality will be important for potential future application in central labs. It will be submitted for an FDA Emergency Use Authorization (EUA) for the enhanced test in February 2021.

Separately, Quotient reported that the timing of its planned CE Mark submission for the Company's Expanded Immunohematology (IH) microarray has been delayed, primarily due to various disruptions and burdens caused by the pandemic. Pandemic related shutdowns and related travel restrictions have significantly affected among other things, the field trials for the microarray The Company now expects to make this CE mark submission in the second quarter of calendar year 2021. Quotient intends to take advantage of the delayed submission to further improve the performance of a small number of the immunohematology tests featured on the IH microarray by testing new enhancements through additional field trials. The Company anticipates that the commercial menu comprising the Expanded IH microarray and the Initial Serological Disease Screening (SDS) microarray should be available to customers in Europe in the fourth quarter of CY2021. This will allow the Company to participate in tenders that customers are expected to conduct towards year end.

The Company also announced, despite COVID-19 disruptions, a strong 9.8% organic growth for Alba by Quotient reagents for the third quarter ended December 31, 2020. The Company's MosaiQ COVID-19 antibody microarray sales reached $0.4 million during the quarter and exceeded $1 million year to date.

The Company reported a strong cash position as of December 31, 2020, with cash and cash equivalents of $143.5 million (including $9 million in restricted cash reserve accounts).  

 

 

The Company won a 2021 BIG Innovation Award, which celebrates innovative organizations and products.

MosaiQ Platform

MosaiQ, Quotient's next-generation platform, is designed to deliver rapid immunohematology, serological and molecular disease screening, using a single low volume sample on a high throughput, multimodal multiplexing automated platform. MosaiQ represents a transformative and potentially highly disruptive unified testing system for transfusion diagnostics and beyond. Feasibility to deliver required performance in serological and molecular disease screening has been demonstrated. MosaiQ offers the potential to significantly reduce complexity and improve workflow for our customers. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 antibody microarray is CE marked and has received FDA emergency use authorization (EUA). It is available for distribution in the U.S. and Europe, including Switzerland and the UK. In addition, the MosaiQ COVID-19 semi-quantitative antibody test recently was CE marked and the Company expects to apply for an FDA EUA for that test in February 2021.

Regulatory and Commercial Milestones

Europe

•

Donor IH Field Trials – When the company reported preliminary results from its Expanded IH microarray European field trials on November 30, 2020, it indicated an intention to make a CE mark application around year end. Subsequently, the Company decided to postpone the CE mark submission for a variety of reasons. The CE mark submission is now expected to take place in Q2 of CY2021. A principal reason for the postponement was the disruptions and burdens caused by the pandemic. For example, an inspection of the manufacturing site by the appropriate regulatory body, which is required for CE marking of this product, is not currently possible. In addition, the Company has determined that the accuracy of some of the tests on the IH microarray is below their potential and can be improved with new enhancements that the Company has identified and intends to implement and then test by performing additional field trials in 2021. The Company presently intends to complete this work and the related field tests, notwithstanding pandemic related disruption, in time to include the results in the CE mark application that it has rescheduled for Q2 of CY2021. Commercial launch is planned for Q4 CY2021.

•

SDS Field Trials – European field trials for the Company's Expanded SDS microarray also have been impacted by pandemic- related disruption. The SDS field trials are now targeted to start towards the end of CY2021 with a CE mark submission targeted in the second quarter of CY2022.

•

Patient IH – The Company is developing an IH microarray for the patient transfusion market which it will sell to Ortho along with instruments and consumables and expects to submit for CE mark in the first half of CY2022.

 

U.S.

•

Donor IH Field Trials – Expanded IH field trials are expected to commence in Q2 CY2021 and BLA submission is anticipated for Q4 CY2021.

 

 

•

Initial SDS Regulatory – US FDA 510(k) resubmission is planned in Q2 CY2021 and FDA clearance for the Initial SDS microarray and the MosaiQ instrument is expected before the end of CY2021. This is not on the critical path of commercialization, as the Company plans to offer the Expanded IH microarray and the Initial SDS as a combined package.


Quotient CEO Franz Walt commented “We are all going through an unprecedented situation, which caused some delays, but we have to look beyond the global crisis and recognize that the underlying business value of the innovative MosaiQ technology remains the same. Despite these adversities, I am proud of the Quotient team, as we continue to deliver and make significant progress towards our goal of commercialization.”


 

 

Fiscal Third Quarter Financial Results

The Alba by Quotient reagent business continues to deliver top line growth, with strong product sales of $8.4 million in the third quarter, up 9.8% from the quarter ended December 31, 2019. This performance was driven by 9.2% growth in sales to original equipment manufacturer (OEM) customers, while direct product sales grew 11.0%. The product sales related to the MosaiQ COVID-19 antibody microarray were $0.4 million in the third quarter.

Other revenues for the quarter ended December 31, 2020 arose on a small development project with an OEM customer. In the quarter ended December 31, 2019 other revenues arose from the achievement of product development milestones under a development contract, which was completed during the year ended March 31, 2020.

In the quarter ended December 31, 2020, gross margin on product sales increased to 43.2% compared to the gross margin on product sales of 42.9% reported in the quarter ended December 31, 2019. Year over year, gross margin was positively impacted mainly by improved product mix and lower levels of materials scrapped.

Key revenue and profit results are summarized below (expressed in thousands, except percentages).

 

 

Quarter Ended

 

 

Nine Months Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales —OEM Customers

 

$

5,536

 

 

$

5,071

 

 

$

16,754

 

 

$

15,354

 

Product sales — direct customers and distributors

 

 

2,846

 

 

 

2,565

 

 

 

8,417

 

 

 

7,547

 

Product sales - MosaiQ

 

 

358

 

 

 

—

 

 

 

1,036

 

 

 

—

 

Other revenues

 

 

11

 

 

 

305

 

 

 

7,534

 

 

 

1,055

 

Total revenue

 

$

8,751

 

 

$

7,941

 

 

$

33,741

 

 

$

23,956

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales from standing orders (%)

 

 

70

%

 

 

72

%

 

 

69

%

 

 

71

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

$

3,781

 

 

$

3,409

 

 

$

18,858

 

 

$

10,889

 

Gross profit as a % of total revenue

 

 

43.2

%

 

 

42.9

%

 

 

55.9

%

 

 

45.5

%

Gross margin on product sales (%)

 

 

43.1

%

 

 

40.6

%

 

 

43.2

%

 

 

42.9

%

Operating (loss)

 

$

(21,725

)

 

$

(22,357

)

 

$

(54,544

)

 

$

(59,221

)

 

The operating loss for the quarter ended December 31, 2020 included inventory provisions of $2.0 million in respect of certain raw material and work-in-progress items following evaluation of clinical trials results and corresponding changes in manufacturing processes. The operating loss for the quarter ended December 31, 2019 included termination and transition benefit costs of approximately $1.3 million; legal and advisory fees related to the Company’s termination of its distribution and supply agreement with Ortho and the related dispute and higher payments to a research and development collaboration partner totaling $0.8 million

Capital expenditures totaled $1.7 million in the quarter ended December 31, 2020, compared with $1.4 million in the quarter ended December 31, 2019.

As at December 31, 2020, Quotient had $143.5 million in cash and other short-term investments (including $9 million in restricted cash reserve accounts) and $159.7 million of debt.

 

 

Outlook for the Fiscal Year Ending March 31, 2021

•

Total product sales of Alba by Quotient reagents are still expected to be in the range of $33.5 to $34 million compared to product sales in fiscal 2020 of $31.6 million.

•

Capital expenditures in the range of $6 to $8 million.

•

Average monthly cash use for operations in the range of $5 to $6 million excluding potential revenue related to COVID-19 antibody test.

Alba by Quotient product sales in the fourth quarter of fiscal 2021 are expected to be within the range of $8.3 to $8.8 million, compared with $8.7 million for the fourth quarter of fiscal 2020.

Quarterly product sales can fluctuate depending upon the shipment cycles for red blood                 cell-based products, which account for approximately two-thirds of current product sales. These products typically experience 13 shipment cycles per year, equating to three shipments of each product per quarter, except for one quarter per year when four shipments occur. The timing of shipment of bulk antisera products to OEM customers may also move revenues from quarter to quarter. Some seasonality in demand is also experienced around holiday periods in both Europe and the United States. As a result of these factors, Quotient expects to continue to see seasonality and quarter-to-quarter variations in product sales.

 

Conference Call

Quotient will host a conference call on Monday, February 1, 2021 at 8:00 a.m. Eastern Time to discuss its third quarter fiscal 2021 financial results. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13715310. The conference call will be webcast live on the Company’s website at www.quotientbd.com.

A replay of this conference call will be available through February 8, 2021 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13715310.


 

 

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

 

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including our expectations regarding the timing and results from field trials of our products under development and the timing of applications for various regulatory clearances required for commercial sales of those products, as well as the potential for using the Company’s MosaiQ technology in infectious disease diagnostics), current estimates of third quarter and full year fiscal 2021 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, are greater than they otherwise would be because of the impact of the COVID-19 pandemic. They include COVID-related delays or disruptions of field trial studies for our products, delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems (not related to COVID with respect to our manufacturing or product development activities or field trial studies; adverse results in connection with any future legal proceedings, continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

The Quotient logo, Quotient MosaiQ and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Peter Buhler, Chief Financial Officer – IR@quotientbd.com; +41 22 545 52 26

 

 

 

 


 

 

Quotient Limited

Condensed Consolidated Statements of Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

Quarter Ended

 

 

Nine Months Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

8,740

 

 

$

7,636

 

 

$

26,207

 

 

$

22,901

 

Other revenues

 

 

11

 

 

 

305

 

 

 

7,534

 

 

 

1,055

 

Total revenue

 

 

8,751

 

 

 

7,941

 

 

 

33,741

 

 

 

23,956

 

Cost of revenue

 

 

4,970

 

 

 

4,532

 

 

 

14,883

 

 

 

13,067

 

Gross profit

 

 

3,781

 

 

 

3,409

 

 

 

18,858

 

 

 

10,889

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

2,283

 

 

 

2,290

 

 

 

6,757

 

 

 

7,123

 

Research and development, net

 

 

14,485

 

 

 

14,160

 

 

 

38,813

 

 

 

38,895

 

General and administrative expense

 

 

8,738

 

 

 

9,316

 

 

 

27,832

 

 

 

24,092

 

Total operating expense

 

 

25,506

 

 

 

25,766

 

 

 

73,402

 

 

 

70,110

 

Operating loss

 

 

(21,725

)

 

 

(22,357

)

 

 

(54,544

)

 

 

(59,221

)

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(6,753

)

 

 

(7,008

)

 

 

(19,537

)

 

 

(20,384

)

Other, net

 

 

192

 

 

 

1,894

 

 

 

5,423

 

 

 

1,600

 

Other expense, net

 

 

(6,561

)

 

 

(5,114

)

 

 

(14,114

)

 

 

(18,784

)

Loss before income taxes

 

 

(28,286

)

 

 

(27,471

)

 

 

(68,658

)

 

 

(78,005

)

Provision for income taxes

 

 

(1,471

)

 

 

(14

)

 

 

(1,503

)

 

 

(41

)

Net loss

 

$

(29,757

)

 

$

(27,485

)

 

$

(70,161

)

 

$

(78,046

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of effective portion of

     foreign currency cash flow hedges

 

$

295

 

 

$

487

 

 

$

571

 

 

$

209

 

Change in unrealized gain on short-term investments

 

 

111

 

 

 

148

 

 

 

(372

)

 

 

342

 

Foreign currency gain (loss)

 

 

2,031

 

 

 

254

 

 

 

(1,270

)

 

 

(771

)

Provision for pension benefit obligation

 

 

13

 

 

 

48

 

 

 

40

 

 

 

144

 

Other comprehensive loss

 

 

2,450

 

 

 

937

 

 

 

(1,031

)

 

 

(76

)

Comprehensive loss

 

$

(27,307

)

 

$

(26,548

)

 

$

(71,192

)

 

$

(78,122

)

Net loss available to ordinary shareholders

     - basic and diluted

 

$

(29,757

)

 

$

(27,485

)

 

$

(70,161

)

 

$

(78,046

)

Loss per share - basic and diluted

 

$

(0.29

)

 

$

(0.37

)

 

$

(0.79

)

 

$

(1.14

)

Weighted-average shares outstanding - basic and

     diluted

 

 

101,016,040

 

 

 

73,768,845

 

 

 

88,512,823

 

 

 

68,722,475

 

 

 

 

 

 

 

 

 

Quotient Limited

Condensed Consolidated Balance Sheets

(In Thousands)

(Unaudited)

 

 

 

December 31,

2020

 

 

March 31, 2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

3,401

 

 

$

3,923

 

Short-term investments

 

 

131,062

 

 

 

116,871

 

Trade accounts receivable, net

 

 

4,539

 

 

 

5,402

 

Inventories

 

 

23,709

 

 

 

20,501

 

Prepaid expenses and other current assets

 

 

4,928

 

 

 

3,775

 

Total current assets

 

 

167,639

 

 

 

150,472

 

Restricted cash

 

 

9,046

 

 

 

9,017

 

Property and equipment, net

 

 

40,894

 

 

 

40,165

 

Operating lease right-of-use assets

 

 

22,364

 

 

 

21,493

 

Intangible assets, net

 

 

632

 

 

 

625

 

Deferred income taxes

 

 

237

 

 

 

237

 

Other non-current assets

 

 

4,914

 

 

 

4,454

 

Total assets

 

$

245,726

 

 

$

226,463

 

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,860

 

 

$

4,826

 

Accrued compensation and benefits

 

 

4,844

 

 

 

7,210

 

Accrued expenses and other current liabilities

 

 

11,351

 

 

 

15,490

 

Current portion of long-term debt

 

 

24,167

 

 

 

—

 

Current portion of operating lease liability

 

 

3,309

 

 

 

3,033

 

Capital lease obligation

 

 

878

 

 

 

598

 

Total current liabilities

 

 

50,409

 

 

 

31,157

 

Long-term debt

 

 

135,490

 

 

 

153,024

 

Operating lease liability, less current portion

 

 

21,203

 

 

 

19,914

 

Capital lease obligation, less current portion

 

 

582

 

 

 

1,117

 

Deferred income taxes

 

 

1,455

 

 

 

—

 

Defined benefit pension plan obligation

 

 

7,707

 

 

 

6,353

 

7% Cumulative redeemable preference shares

 

 

21,213

 

 

 

20,425

 

Total liabilities

 

 

238,059

 

 

 

231,990

 

Total shareholders' equity (deficit)

 

 

7,667

 

 

 

(5,527

)

Total liabilities and shareholders' equity (deficit)

 

$

245,726

 

 

$

226,463

 

 

 

 

 

 

 

 

Quotient Limited

Condensed Consolidated Statements of Cash Flows

(In Thousands)

(Unaudited)

 

 

 

Nine months ended December 31,

 

 

 

2020

 

 

2019

 

OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(70,161

)

 

$

(78,046

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,484

 

 

 

8,996

 

Share-based compensation

 

 

3,498

 

 

 

3,375

 

Increase (decrease) in deferred lease rentals

 

 

512

 

 

 

215

 

Swiss pension obligation

 

 

776

 

 

 

551

 

Amortization of deferred debt issue costs

 

 

6,633

 

 

 

7,736

 

Accrued preference share dividends

 

 

788

 

 

 

788

 

Income taxes

 

 

1,503

 

 

 

41

 

Net change in assets and liabilities:

 

 

 

 

 

 

 

 

Trade accounts receivable, net

 

 

1,268

 

 

 

(1,638

)

Inventories

 

 

(1,218

)

 

 

(3,838

)

Accounts payable and accrued liabilities

 

 

(3,670

)

 

 

(2,268

)

Accrued compensation and benefits

 

 

(2,825

)

 

 

(268

)

Other assets

 

 

(330

)

 

 

(406

)

Net cash used in operating activities

 

 

(56,742

)

 

 

(64,762

)

INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Increase in short-term investments

 

 

(72,247

)

 

 

(95,000

)

Realization of short-term investments

 

 

57,683

 

 

 

52,700

 

Purchase of property and equipment

 

 

(3,602

)

 

 

(3,941

)

Purchase of intangible assets

 

 

—

 

 

 

—

 

Net cash generated from investing activities

 

 

(18,166

)

 

 

(46,241

)

FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Repayment of finance leases

 

 

(491

)

 

 

(337

)

Proceeds from drawdown of new debt

 

 

—

 

 

 

25,000

 

Debt issuance costs and fees paid to noteholders

 

 

—

 

 

 

(874

)

Proceeds from issuance of ordinary shares and warrants

 

 

80,888

 

 

 

90,728

 

Net cash (used in) generated from financing activities

 

 

80,397

 

 

 

114,517

 

Effect of exchange rate fluctuations on cash and cash equivalents

 

 

(5,982

)

 

 

(1,438

)

Change in cash and cash equivalents

 

 

(493

)

 

 

2,076

 

Beginning cash and cash equivalents

 

 

12,940

 

 

 

11,603

 

Ending cash and cash equivalents

 

$

12,447

 

 

$

13,679

 

Supplemental cash flow disclosures:

 

 

 

 

 

 

 

 

Income taxes paid

 

$

—

 

 

$

—

 

Interest paid

 

$

17,499

 

 

$

15,959

 

Reconciliation of cash, cash equivalents and restricted cash:

 

 

 

 

 

 

 

 

  Cash and cash equivalents

 

$

3,401

 

 

$

4,664

 

  Restricted cash

 

 

9,046

 

 

 

9,015

 

Total cash, cash equivalents and restricted cash

 

$

12,447

 

 

$

13,679

 

 

 

 GRAPHIC 3 gcjh2i4vii5l000001.jpg GRAPHIC begin 644 gcjh2i4vii5l000001.jpg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qtnt-20210201.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 qtnt-20210201_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, Address Line Three Entity Address Address Line3 Entity Address, City or Town Entity Address City Or Town Entity Address, Country Entity Address Country Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 qtnt-20210201_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 qtnt-8k_20210201_htm.xml IDEA: XBRL DOCUMENT 0001596946 2021-02-01 2021-02-01 false Quotient Ltd 0001596946 00-0000000 8-K 2021-02-01 Y9 001-36415 B1 Business Park Terre Bonne Route de Crassier 13 1262 Eysins CH 011-41 22-716-9800 false false false false Ordinary Shares, nil par value QTNT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Feb. 01, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 01, 2021
Entity Registrant Name Quotient Ltd
Entity Central Index Key 0001596946
Entity Emerging Growth Company false
Entity File Number 001-36415
Entity Incorporation State Country Code Y9
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One B1
Entity Address, Address Line Two Business Park Terre Bonne
Entity Address, Address Line Three Route de Crassier 13
Entity Address, City or Town Eysins
Entity Address, Country CH
Entity Address, Postal Zip Code 1262
City Area Code 011-41
Local Phone Number 22-716-9800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Ordinary Shares, nil par value
Trading Symbol QTNT
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports qtnt-8k_20210201.htm qtnt-20210201.xsd qtnt-20210201_lab.xml qtnt-20210201_pre.xml qtnt-ex991_25.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "qtnt-8k_20210201.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "qtnt-8k_20210201.htm" ] }, "labelLink": { "local": [ "qtnt-20210201_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "qtnt-20210201_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "qtnt-20210201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "qtnt", "nsuri": "http://www.quotientbd.com/20210201", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "qtnt-8k_20210201.htm", "contextRef": "C_0001596946_20210201_20210201", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "qtnt-8k_20210201.htm", "contextRef": "C_0001596946_20210201_20210201", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address Address Line3", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "verboseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.quotientbd.com/20210201/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001564590-21-003480-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-003480-xbrl.zip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�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